DIAmOND / BCT 1703

This study will investigate the addition of two monoclonal antibodies (tremelimumab and durvalumab) to the standard treatment after breast cancer progression.

Category
Trial Status
Recruiting
Trial Phase
Phase 2 Drug Trial
Registry Listing
ERM Project ID
55403
Trial contact details
Contact Person
Donna Harvey
What you need to know

Who can take part?

Patients with breast cancer which is HER2-positive type that has progressed, or spread, to other areas around the breast (locally advanced) or to other parts of your body (metastatic). 

What is involved for you?

The trial goes for 52 weeks during which you will see your doctor and research coordinator approximately every three weeks  for physical exams, ECG's blood tests, tumour assessments (ie-CT scans) and heart function tests. You will receive  medicine injected into your veins every 3-4 weeks.

All research clinical trials news

When Monique Perry was diagnosed with aggressive triple-negative breast cancer she feared her family history was about to repeat itself.

27

Oct

Clinical trials give Queensland breast cancer patients hope

Mater researchers in Brisbane are leading a trial of a game-changing flu vaccine that has the potential to provide greater and more durable protection against the virus.

23

May

Mater launches trial of Australian-first flu vaccine

Stephanie Guilas has worked in many departments throughout Mater Hospital Brisbane, however, after 28 years of service, she found her true passion working within Mater Research’s Mothers and Babies...

19

May

Stephanie Guilas is improving outcomes for mums and bubs through research

Displaying results 1-3 (of 17)
 |<  < 1 - 2 - 3 - 4 - 5 - 6  >  >|